Table 1

Baseline characteristics of study patients at the time of canagliflozin or dapagliflozin initiation and mean change from baseline in clinical outcomes at 3 and 6 months

ParametersCanagliflozin (N = 290)Dapagliflozin (N = 121)
BaselineΔ BL-3MP valueΔ BL-6MP valueBaselineΔ BL-3MP valueΔ BL-6MP value
HbA1c, %9.03 ± 1.5−0.69<0.00−0.88<0.009.13 ± 1.5−0.59<0.00−0.71<0.00
HbA1c, mmol/mol75.2 ± 15.9−7.00<0.00−9.00<0.0076.3 ± 15.9−6.00<0.00−8.00<0.00
HbA1c at target,* %0.015.5<0.0021.1<0.000.013.30.0010.00.00
Weight, kg107.2 ± 27.8−1.400.00−2.99<0.00102.2 ± 22.9−0.960.00−1.60<0.00
SBP, mmHg131.7 ± 16.1−5.10<0.00−6.40<0.00128.8 ± 14.2−7.97<0.00−4.700.00
DBP, mmHg76.4 ± 9.4−3.35<0.00−2.300.0076.9 ± 9.9−5.79<0.00−1.430.21
LDL-C, mmol/L1.9 ± 0.7−0.010.70−0.010.871.9 ± 0.8−0.120.07−0.150.03
HDL-C, mmol/L1.1 ± 0.30.020.050.020.071.1 ± 0.3−0.000.650.010.18
TC, mmol/L3.9 ± 1.1−0.010.840.000.944.2 ± 1.5−0.120.11−0.150.05
TG, mmol/L2.3 ± 2.4−0.060.26−0.080.143.1 ± 4.0−0.140.14−0.150.09
ACR, mg/mmol15.3 ± 59.8−3.200.31−0.560.8511.0 ± 23.60.300.82−0.030.97
eGFR, mL/min87.5 ± 16.4−3.39<0.00−2.900.0089.5 ± 16.4−0.460.74−0.910.51
SCr, µmol/L68.2 ± 16.43.64<0.003.24<0.0069.4 ± 15.72.190.072.600.03
K, mmol/L4.4 ± 0.40.080.000.070.014.5 ± 0.50.030.380.030.34
Insulin/day, IU98.2 ± 83.8−5.190.05−5.800.0390.1 ± 67.8−3.400.36−5.440.20
 Basal228 (78.6)96 (79.2)
 Prandial56 (19.5)25 (20.8)
 Premixed6 (1.9)0 (0)
Insulin/day, IU
 0–100190 (65.5)1.530.550.760.7785 (70.2)0.220.94−0.360.90
 101–20073 (25.2)−17.22<0.00−17.00.0029 (23.8)2.40.84−4.050.05
 >20027 (9.4)−21.380.29−23.10.267 (5.9)−77.40.02−71.00.03
Insulin/weight/day, IU/kg/day
 0.1–0.480 (27.5)0.030.250.060.0027 (22.6)0.070.180.080.12
 0.5–1.0111 (38.2)−0.060.09−0.020.6059 (48.4)0.040.440.010.79
 1.1–2.077 (26.4)−0.150.00−0.130.0127 (22.6)−0.050.69−0.100.42
 >2.023 (7.9)−0.340.28−0.390.208 (6.5)−0.570.01−0.550.01
  • Baseline values are mean ± SD or n (%) unless otherwise indicated. Δ BL-3M, mean change from baseline in clinical outcomes at 3 months; Δ BL-6M, mean change from baseline in clinical outcomes at 6 months; ACR, albumin-to-creatinine ratio; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, HDL cholesterol; K, potassium; LDL-C, LDL cholesterol; SBP, systolic blood pressure; SCr, serum creatinine; TC, total cholesterol; TG, triglycerides.

  • * HbA1c <7% (<53 mmol/mol).